GT BIOPHARMA, INC. Increase (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31)
GT BIOPHARMA, INC. (GTBP) reported Increase (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) of $0 for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-21.
Discontinued › Notes › Derivative Instruments and Hedging Activities
us-gaap:IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments · last filed 2012-11-21
- GT BIOPHARMA, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for the quarter ending 2012-09-30 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for the quarter ending 2012-06-30 was -$212.00K.
- GT BIOPHARMA, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for the quarter ending 2012-03-31 was -$145.00K, a 240.78% decline year-over-year.
- GT BIOPHARMA, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for the quarter ending 2011-12-31 was $1.00K.
- GT BIOPHARMA, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for fiscal 2011 was $784.00K, a 5126.67% increase from fiscal 2010.
- GT BIOPHARMA, INC. increase (decrease) in fair value of derivative instruments, not designated as hedging instruments (deprecated 2013-01-31) for fiscal 2010 was $15.00K.
| Period end | Increase (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 3 month | Increase (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 6 month | Increase (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 9 month | Increase (Decrease) in Fair Value of Derivative Instruments, Not Designated as Hedging Instruments (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2012-09-30 | $0.00 10-Q · filed 2012-11-21 | -$212.00K derived: sum of 2 quarters · filed 2012-11-21 | -$358.00K 10-Q · filed 2012-11-21 | -$356.00K derived: sum of 4 quarters · filed 2012-11-21 |
| 2012-06-30 | -$212.00K 10-Q/A · filed 2012-09-13 | -$357.00K 10-Q/A · filed 2012-09-13 | -$356.00K derived: sum of 3 quarters · filed 2012-09-13 | $325.00K derived: sum of 4 quarters · filed 2012-11-21 |
| 2012-03-31 | -$145.00K 10-Q · filed 2012-05-21 | -$144.00K derived: sum of 2 quarters · filed 2012-05-21 | $537.00K derived: sum of 3 quarters · filed 2012-11-21 | $536.00K derived: sum of 4 quarters · filed 2012-11-21 |
| 2011-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | $682.00K derived: sum of 2 quarters · filed 2012-11-21 | $681.00K derived: sum of 3 quarters · filed 2012-11-21 | $784.00K 10-K · filed 2012-04-16 |
| 2011-09-30 | $681.00K 10-Q · filed 2012-11-21 | $680.00K derived: sum of 2 quarters · filed 2012-11-21 | $783.00K 10-Q · filed 2012-11-21 | $739.00K derived: sum of 4 quarters · filed 2012-11-21 |
| 2011-06-30 | -$1.00K 10-Q/A · filed 2012-09-13 | $102.00K 10-Q/A · filed 2012-09-13 | $58.00K derived: sum of 3 quarters · filed 2012-09-13 | $102.00K derived: sum of 4 quarters · filed 2012-09-13 |
| 2011-03-31 | $103.00K 10-Q · filed 2012-05-21 | $59.00K derived: sum of 2 quarters · filed 2012-05-21 | $103.00K derived: sum of 3 quarters · filed 2012-05-21 | $876.00K derived: sum of 4 quarters · filed 2012-05-21 |
| 2010-12-31 | -$44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | $0.00 derived: sum of 2 quarters · filed 2012-04-16 | $773.00K derived: sum of 3 quarters · filed 2012-04-16 | $15.00K 10-K · filed 2012-04-16 |
| 2010-09-30 | $44.00K 10-Q · filed 2011-11-21 | $817.00K derived: sum of 2 quarters · filed 2011-11-21 | $59.00K 10-Q · filed 2011-11-21 | |
| 2010-06-30 | $773.00K 10-Q/A · filed 2011-09-12 | $0.00 10-Q/A · filed 2011-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |